For some reason your most recent comment is dead, and I cannot reply to it, so I'll reply here.
It looks like the funding did cover the WIV research, from what I understand the article to say.
"The NIH research consisted of two parts. The first part began in 2014 and involved surveillance of bat coronaviruses, and had a budget of $3.7 million. The program funded Shi Zheng-Li, a virologist at the Wuhan lab, and other researchers to investigate and catalogue bat coronaviruses in the wild. This part of the project was completed in 2019."
Here's the 2015 paper co-authored by Zheng-Li Shi detailing a chimeric coronavirus that uses the SARS backbone to target ACE2, very similar to how covid-19 operates.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797993/
"Using the SARS-CoV reverse genetics system2, we generated and characterized a chimeric virus expressing the spike of bat coronavirus SHC014 in a mouse-adapted SARS-CoV backbone. The results indicate that group 2b viruses encoding the SHC014 spike in a wild-type backbone can efficiently use multiple orthologs of the SARS receptor human angiotensin converting enzyme II (ACE2), replicate efficiently in primary human airway cells and achieve in vitro titers equivalent to epidemic strains of SARS-CoV."
It makes me confused regarding the recent debunking article that claims there is no way humans can have engineered the covid-19 spike that targets ACE2, and there is no known backbone used in the covid-19 genome. Seems in contradiction to this 2015 paper.